New Horizon Europe Cancer Mission Project: SHIELD – Early Detection of Pancreatic Cancer
The Health Technologies Division of I-SENSE Group/ICCS is proud to participate in the newly launched Cancer Mission project SHIELD – Comprehensive Surveillance of High-risk Individuals and Health Integration for Early detection of Pancreatic cancer utilising innovative multiplex immunoassays, funded under the HORIZON-MISS-2024-CANCER-01-03 call of the Horizon Europe programme.
SHIELD aims to revolutionize early detection of pancreatic ductal adenocarcinoma (PDAC), particularly in individuals with a high genetic or familial risk. With a 5-year survival rate below 10% due to late diagnosis, SHIELD introduces a novel blood-based diagnostic test using 5-plex immunoassays to detect protein biomarkers that indicate early-stage PDAC.
- Start Date: 1 May 2025
- Duration: 48 months
- Consortium Size: 27 partners
- Countries Involved: 16 across Europe
- Sectors Represented: Academia, hospitals, research institutes, health authorities, technology companies, patient organization
ICCS participates in SHIELD with two departments: the Biomedical Engineering Laboratory (https://www.biomed.ntua.gr/) and the Health Technologies Division of I-SENSE. Our group will contribute to several activities of the project, with a focus on the development of an AI-empowered Platform for recruitment and surveillance of high-risk individuals.
Through its involvement, ICCS brings extensive experience in health-related digital innovation, strengthening the project’s impact and reliability.
